Home › All Companies › CHRS › Annual Report

Coherus Oncology, Inc. (CHRS) — Annual Report

AI-Powered SEC Filing Analysis

← All CHRS filings
Latest Annual Report Filed: 2026-03-09

Key Insights

  • Coherus Oncology, Inc. reported a significant increase in research and development expenses in 2025, suggesting a focus on advancing their oncology pipeline.
  • The company recorded a non-operating gain from the sale of its Yusimry Immunology Franchise, which may provide financial flexibility to support ongoing operations.
  • Coherus Oncology's revenue from the Toripalimab product declined in 2025 compared to the previous year, which could indicate increasing competitive pressures in the market.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-09. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Coherus Oncology, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.